情报报告

HLTH panelists say AI should not issue prior authorization denials

Panelists at HLTH agreed that a licensed human, not an algorithm, should decide medical necessity, but split over who that human should be.

INSIGHTEX Editorial Desk

阅读约 2 分钟

HLTH panelists say AI should not issue prior authorization denials情报报告

What happened

Panelists at the HLTH conference agreed that artificial intelligence should not have the final word on medical-necessity decisions in prior authorization, MedCity News reported. Sean Robbins, executive vice president and chief operating officer of the Blue Cross Blue Shield Association, said a licensed clinician should make the decision. He said that clinician may use AI as an aid but should not merely review a call the software has made.

Dr. Warris Bokhari, chief executive of Claimable, a company that helps patients appeal rejected health insurance claims, agreed that a qualified person should decide denials. He argued that in oncology that person should be the treating physician, not an insurer reviewer who has never met the patient. He called for ways to hold plans accountable and alleged that Blue Cross and Blue Shield of Illinois denied liver transplants for cancer patients using evidence that included 1994 case data.

Robbins replied that he does not want an inappropriate denial in any situation. He said accountability and transparency matter and that the industry must get correct answers to the right people quickly. Dr. Mandy Cohen, a national advisor at Manatt Health, said the prior authorization model should be rethought rather than simply sped up. She linked the problem to payment incentives and acknowledged that providers do sometimes request low-value care.

Context

Prior authorization is a frequent point of conflict between payers and providers. Cohen noted that insurers keep these guardrails in part because some providers ask for low-value care, and she argued that the underlying payment incentives drive the problem. Claimable works on the patient side of this dispute by helping people contest denied claims, which puts it in direct tension with insurer review practices.

来源MedCity News

简报

一封邮件,尽览一周科技要闻。

每周精选值得一读的报道。可随时退订。